Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

STIL Block Versus Paravertebral Block for Pain Relief After Modified Radical Mastectomy (STIL-PVB-MRM)

16 novembre 2026 mis à jour par: Armia mohsen shafeek, National Cancer Institute, Egypt

Ultrasound-Guided Subtransverse Interligamentary (STIL) Block Versus Paravertebral Block (PVB) for Postoperative Analgesia in Modified Radical Mastectomy: A Randomized Controlled Trial

Breast cancer surgery, particularly modified radical mastectomy (MRM), can cause significant postoperative pain. Effective pain management is important to improve patient comfort, facilitate recovery, reduce opioid consumption, and potentially decrease the risk of persistent post-mastectomy pain.

This randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided subtransverse interligamentary (STIL) block and thoracic paravertebral block (PVB) for postoperative pain relief in female patients undergoing modified radical mastectomy.

Eligible patients will be randomly allocated into three groups: the STIL block group, the PVB group, and a control group receiving general anesthesia without a regional block. Both regional blocks will be performed under ultrasound guidance at the T4 thoracic level using 25 mL of 0.25% bupivacaine combined with 4 mg dexamethasone.

Postoperative pain will be assessed using a visual analogue scale (VAS) at rest and during movement. The study will also evaluate postoperative morphine consumption, time to first rescue analgesia, intraoperative fentanyl requirements, recovery characteristics, patient satisfaction, postoperative nausea and vomiting, and block-related complications.

The primary objective is to compare postoperative pain scores at rest 24 hours after surgery between patients receiving STIL block and those receiving PVB.

The findings may help determine whether STIL block provides an effective alternative to thoracic paravertebral block for postoperative analgesia following modified radical mastectomy.

Aperçu de l'étude

Description détaillée

BACKGROUND AND RATIONALE:

Modified radical mastectomy (MRM) is a commonly performed surgical procedure for the management of breast cancer. Postoperative pain remains an important concern and may interfere with respiratory function, delay mobilization, prolong hospital stay, and negatively affect patient recovery and satisfaction.

Thoracic paravertebral block (PVB) is an established regional anesthesia technique for breast surgery that provides effective postoperative analgesia and reduces opioid requirements. However, it requires considerable technical expertise and carries potential complications, including pleural puncture, pneumothorax, vascular injury, and inadvertent neuraxial spread of local anesthetic.

The ultrasound-guided subtransverse interligamentary (STIL) block is a relatively novel paraspinal regional anesthesia technique. Local anesthetic is injected into the space between the transverse process and the intertransverse ligament, allowing spread toward the thoracic paravertebral space.

This study aims to compare the postoperative analgesic efficacy of STIL block with thoracic PVB in patients undergoing MRM.

STUDY DESIGN AND POPULATION:

This is a prospective, randomized, controlled clinical trial involving 60 female patients with breast cancer scheduled for modified radical mastectomy at the National Cancer Institute, Cairo University.

Eligible patients will be aged 18-65 years, have an ASA physical status of II-III, and a body mass index between 20 and 35 kg/m².

Patients will be randomly allocated into three equal groups, with 20 patients in each group:

Group I - STIL Block:

Patients will receive ultrasound-guided subtransverse interligamentary block at the T4 thoracic level before induction of general anesthesia.

Group II - Paravertebral Block:

Patients will receive ultrasound-guided thoracic paravertebral block at the T4 thoracic level before induction of general anesthesia.

Group III - Control:

Patients will receive general anesthesia without any regional nerve block.

INTERVENTION DETAILS:

Both regional anesthesia techniques will be performed approximately 30 minutes before induction of general anesthesia.

In the STIL group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the subtransverse interligamentary space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

In the PVB group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the thoracic paravertebral space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

All patients will receive standardized general anesthesia and multimodal postoperative analgesia according to the study protocol.

GENERAL ANESTHESIA AND POSTOPERATIVE ANALGESIA:

General anesthesia will be induced using intravenous propofol, fentanyl, and rocuronium and maintained with sevoflurane in oxygen-enriched air.

All patients will receive intravenous paracetamol 1 g and ketorolac 30 mg as part of the multimodal analgesic regimen, subject to suitability.

Postoperative analgesia will include intravenous paracetamol 1 g and ketorolac 30 mg every 8 hours. Rescue analgesia will be provided using intravenous morphine 3 mg increments whenever the visual analogue scale (VAS) pain score is ≥4.

OUTCOME ASSESSMENT:

Primary Outcome:

The primary outcome is the postoperative pain score at rest, assessed using the visual analogue scale (VAS) 24 hours after surgery, comparing the STIL and PVB groups.

Secondary Outcomes:

  1. Postoperative pain scores at rest and during movement at predefined time points.
  2. Total postoperative morphine consumption during the first 24 hours.
  3. Time to first rescue analgesic request.
  4. Total intraoperative fentanyl consumption.
  5. Hemodynamic parameters, including heart rate and mean arterial pressure.
  6. Dermatomal sensory distribution and block failure rate.
  7. Block performance time, number of needle passes, and number of attempts.
  8. Postoperative nausea and vomiting.
  9. Patient satisfaction with postoperative analgesia.
  10. Recovery characteristics.
  11. Block-related complications and adverse events.

BLINDING AND RANDOMIZATION:

Patients will be randomly allocated using a computer-generated randomization sequence and sequentially numbered opaque sealed envelopes.

The study will be double-blinded. Patients and postoperative outcome assessors will be unaware of group allocation. Regional blocks will be performed by an anesthesiologist who will not participate in postoperative data collection. Identical adhesive dressings will be applied to the thoracic area in all patients.

STATISTICAL ANALYSIS:

Data will be analyzed using IBM SPSS Statistics version 27. Appropriate parametric and nonparametric statistical tests will be used according to data distribution. A p-value ≤0.05 will be considered statistically significant.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Cairo, Egypte, 11796
        • Recrutement
        • National Cancer Institute, Cairo University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

**Inclusion Criteria:**

  1. Female patients scheduled for modified radical mastectomy for breast cancer.
  2. American Society of Anesthesiologists (ASA) physical status II-III.
  3. Age between 18 and 65 years.
  4. Body mass index (BMI) between 20 and 35 kg/m².

**Exclusion Criteria:**

  1. Patient refusal to participate.
  2. ASA physical status IV or higher.
  3. Age below 18 or above 65 years.
  4. BMI below 20 or above 35 kg/m².
  5. Known allergy to local anesthetics, opioids, or any of the study medications.
  6. History of chronic pain or psychiatric illness.
  7. Contraindications to regional anesthesia, including local infection at the injection site, coagulopathy, or pre-existing neuropathy.
  8. Severe cardiac, hepatic, renal, or respiratory disease.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: STIL Block Group

Patients will receive ultrasound-guided Subtransverse Interligamentary (STIL) block at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Ultrasound-guided Subtransverse Interligamentary (STIL) block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane beneath the intertransverse ligament into the subtransverse interligamentary space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Comparateur actif: Paravertebral Block Group

Patients will receive ultrasound-guided thoracic Paravertebral Block (PVB) at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Ultrasound-guided thoracic paravertebral block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane toward the thoracic paravertebral space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Aucune intervention: Control Group

Patients will receive general anesthesia without any regional anesthesia block. Intraoperative and postoperative analgesia will be provided according to the standardized multimodal analgesic protocol, including intravenous paracetamol and ketorolac, with intravenous morphine as rescue analgesia when the VAS pain score is ≥4.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Postoperative Pain Score at Rest at 24 Hours
Délai: 24 hours after surgery

Postoperative pain intensity at rest will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain), 24 hours after surgery. The primary comparison will be between the STIL block and paravertebral block groups.

24 hours after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Postoperative Pain Scores at Rest and During Movement
Délai: PACU, 1, 2, 4, 6, 12, and 18 hours after surgery

Pain intensity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, both at rest and during movement.

PACU, 1, 2, 4, 6, 12, and 18 hours after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Armia M shafeek, MD, National Cancer Institute, Cairo

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 novembre 2026

Achèvement primaire (Estimé)

1 novembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

16 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared with other researchers because no data-sharing plan has been established for this study. Study results will be disseminated through scientific publications, while participant confidentiality and data privacy will be maintained in accordance with institutional ethical requirements.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner